PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• PepGen received an average analyst rating of “Moderate Buy” from six research firms, with five buy ratings and one sell rating. The average 12-month price target is $11.80.
• Recent analyst moves were mixed: Guggenheim raised its target to $7 and kept a buy rating, Wedbush cut its target to $5 but maintained outperform, and Oppenheimer initiated coverage with a $15 target and outperform rating. Weiss Ratings reiterated a sell (d-) rating.
• The stock was down 3.0% to $1.79, near its 52-week low of $1.01 and well below its 52-week high of $7.80. PepGen also reported a smaller-than-expected quarterly loss, posting $(0.27) EPS versus the estimated $(0.40).

Shares of PepGen, Inc. (NASDAQ:PEPG - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $11.80.

Several equities research analysts recently issued reports on the company. Guggenheim increased their price objective on PepGen from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Wednesday, February 18th. Wedbush reduced their price objective on PepGen from $9.00 to $5.00 and set an "outperform" rating for the company in a research note on Tuesday, March 31st. Oppenheimer assumed coverage on PepGen in a research note on Wednesday, February 25th. They issued an "outperform" rating and a $15.00 price objective for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of PepGen in a research note on Tuesday, April 21st.

Institutional Investors Weigh In On PepGen

Hedge funds and other institutional investors have recently made changes to their positions in the company. Heights Capital Management Inc. purchased a new stake in shares of PepGen during the 3rd quarter worth about $46,000. Burkehill Global Management LP purchased a new stake in shares of PepGen during the 3rd quarter worth about $46,000. China Universal Asset Management Co. Ltd. raised its stake in shares of PepGen by 94.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,202 shares of the company's stock worth $73,000 after purchasing an additional 5,453 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in shares of PepGen during the 4th quarter worth about $89,000. Finally, Militia Capital Partners LP purchased a new stake in shares of PepGen during the 3rd quarter worth about $72,000. 58.01% of the stock is owned by hedge funds and other institutional investors.

PepGen Stock Down 3.0%

Shares of PEPG stock opened at $1.79 on Friday. PepGen has a fifty-two week low of $1.01 and a fifty-two week high of $7.80. The stock has a market capitalization of $123.81 million, a P/E ratio of -0.74 and a beta of 2.01. The stock has a 50-day simple moving average of $3.52 and a 200 day simple moving average of $4.82.

PepGen (NASDAQ:PEPG - Get Free Report) last announced its earnings results on Wednesday, March 4th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.13. On average, sell-side analysts anticipate that PepGen will post -1.22 earnings per share for the current year.

About PepGen

PepGen, Inc NASDAQ: PEPG is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.